专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110045514A1 METHODS FOR DETECTING MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS 审中-公开
标题翻译：检测主要不良心血管事件和脑血管事件的方法
公开(公告)号：US20110045514A1
公开(公告)日：2011-02-24
申请号：US12682492
申请日：2008-10-10
申请人： Pieter Muntendam , Rajalakshmi Balasubramanian , Rene Myers
发明人： Pieter Muntendam , Rajalakshmi Balasubramanian , Rene Myers
IPC分类号： C12Q1/48 , G01N33/49 , G06F19/00
CPC分类号： G01N33/6893 , G01N2333/7454 , G01N2800/2871 , G01N2800/32 , G01N2800/325 , G01N2800/60 , H01J49/0009
摘要： The present teachings relate to a method of assessing the probability of a major adverse cardiovascular or cerebrovascular event in a human. The method can include measuring a concentration, in a blood-based sample of a human, of a set of analytes, for example, alpha-fetoprotein, cancer antigen 125, glutathione S-transferase, and tissue factor. The method also can include determining a MACCE index for the set of analytes and identifying the human as having an increased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is greater than zero, or a decreased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is less than or equal to zero.
摘要翻译：本教导涉及评估人类主要不利心血管或脑血管事件概率的方法。该方法可以包括测量一组分析物例如甲胎蛋白，癌抗原125，谷胱甘肽S-转移酶和组织因子中人血液样品中的浓度。该方法还可以包括确定该组分析物的MACCE指数，并且如果MACCE指数大于零，则将人识别为具有增加的主要不利心血管或脑血管事件的可能性，或主要不利心血管或如果MACCE指数小于或等于零，脑血管事件。

2. 发明申请

US20200345759A1 METHODS OF TREATING GALECTIN-3 DEPENDENT DISORDERS 审中-公开
公开(公告)号：US20200345759A1
公开(公告)日：2020-11-05
申请号：US16933043
申请日：2020-07-20
申请人： Pieter Muntendam , RENSSELAER POLYTECHNIC INSTITUTE
发明人： Robert Linhardt , Jing Zhao , Fuming Zhang , Pieter Muntendam
IPC分类号： A61K31/715 , A61K36/42
摘要： A therapeutic composition includes a polysaccharide, isolated from a member of the genus Cucurbita, e.g., pumpkin, having a backbone including alternating α-L-rhamnosyl (α-L-Rhap) and α-D-galactopyranosyluronic acid (α-D-GapA) residues, and a side chain attached to the backbone including β-D-galactan (β-D-Galp), α-L-arabinofuranosyl (α-L-Araf), or combinations thereof, and a pharmaceutically acceptable excipient. A β-D-Galp side chain is attached to the backbone at the C-4 carbon of at least one α-L-Rhap of the backbone. At least one α-L-Araf is attached to the β-D-Galp side chain. The α-L-Araf is attached to the β-D-Galp side chain via the C-3 carbon of the β-D-Galp. The polysaccharide is effective for treating a galectin-3 dependent disorder by binding to the carbohydrate recognition domain of galectin-3, resulting in inhibition of galectin-3 activity.

3. 发明申请

US20130029955A1 INHIBITORS OF GALECTIN-3 AND METHODS OF USE THEREOF 审中-公开
标题翻译： GALECTIN-3的抑制剂及其使用方法
公开(公告)号：US20130029955A1
公开(公告)日：2013-01-31
申请号：US13480077
申请日：2012-05-24
申请人： Pieter Muntendam
发明人： Pieter Muntendam
IPC分类号： A61K31/585 , A61K31/7016 , G06Q50/22 , G01N33/566 , G01N21/64 , A61K31/70 , A61K31/732
CPC分类号： A61K31/70 , A23L29/231 , A23L33/10 , A23V2002/00 , A61K31/00 , A61K31/7004 , A61K31/7016 , A61K31/702 , A61K31/732 , G01N33/6893 , G01N2333/4724 , G01N2500/02 , G01N2800/325 , G01N2800/52 , A23V2200/326 , A23V2250/5072
摘要： Described herein are methods and compositions for inhibiting galectin-3 in a subject. Also described are methods and compositions for treating heart failure.
摘要翻译：本文描述了用于抑制受试者中半乳凝素-3的方法和组合物。还描述了用于治疗心力衰竭的方法和组合物。

4. 发明申请

US20190151379A1 ENZYME COMPOSITION AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF GALECTIN-3 DEPENDENT DISORDERS 审中-公开
公开(公告)号：US20190151379A1
公开(公告)日：2019-05-23
申请号：US16197000
申请日：2018-11-20
申请人： Pieter Muntendam
发明人： Pieter Muntendam
IPC分类号： A61K35/741 , A61K9/00 , A61P35/00 , A61P9/00 , A61P11/00 , A23L33/135 , A23L29/231 , A61K31/732
摘要： Methods for the prevention or treatment of a galectin-3 mediated or dependent condition in a subject are provided. The methods include orally administering a first amount of a carbohydrate material to the subject and orally administering a second amount of a selected carbohydrate digesting enzyme to the subject. The methods further include enzymatically converting the carbohydrate material into one or more bioactive fragments and producing the one or more bioactive fragments in an amount sufficient to therapeutically inhibit galectin-3 in the subject.

5. 发明申请

US20130244892A1 Risk Factors and Prediction of Adverse Events 审中-公开
标题翻译：风险因素和不良事件的预测
公开(公告)号：US20130244892A1
公开(公告)日：2013-09-19
申请号：US13765366
申请日：2013-02-12
申请人： Aram S. Adourian , Yu Guo , Xiaohong Li , Pieter Muntendam
发明人： Aram S. Adourian , Yu Guo , Xiaohong Li , Pieter Muntendam
IPC分类号： G06F19/00
CPC分类号： G16H50/20 , G01N33/6893 , G01N2333/4713 , G01N2333/4737 , G01N2333/705 , G01N2333/775 , G01N2333/79 , G01N2800/2871 , G01N2800/324 , G01N2800/325 , G01N2800/50
摘要： Biomarkers, methods, systems, and related teachings are disclosed for diagnosing the risk of an adverse event in a human, where the adverse event can be unstable angina, ischemic stroke, non-ischemic stroke, all-cause stroke, heart failure, all-cause death, and being a candidate for coronary revascularization surgery.
摘要翻译：公开了生物标志物，方法，系统和相关教导，用于诊断人类不良事件的风险，其中不良事件可以是不稳定型心绞痛，缺血性中风，非缺血性中风，全因性中风，心力衰竭，导致死亡，并成为冠状动脉血运重建手术的候选人。

6. 发明授权

US5697112A Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications 失效
标题翻译：治疗枕头可用于治疗胃食管反流病（gerd）等应用
公开(公告)号：US5697112A
公开(公告)日：1997-12-16
申请号：US745566
申请日：1996-11-08
申请人： Barbara J. Colavito , Pieter Muntendam
发明人： Barbara J. Colavito , Pieter Muntendam
IPC分类号： A47C20/00 , A47C20/02 , A47C27/18 , A47D5/00 , A47G9/00 , A47G9/10 , A61G7/057 , A61G7/065
CPC分类号： A47C20/027 , A47C27/085 , A47C27/148 , A47C27/18 , A47D5/00 , A47G9/10 , A61G7/065 , A47G2009/008 , A61G7/05715
摘要： A therapy pillow comprising a wedge-shaped resilient foam element having a planar recess in the medial portion of the top surface thereof. A flexible plastic container adapted to be sealingly filled with a fluid snugly fits into the planar recess of the foam element so as to be substantially coplanar with the top surface thereof when filled with a suitable fluid such as water.
摘要翻译：一种治疗用枕头，其包括在其顶部表面的中间部分中具有平面凹部的楔形弹性泡沫元件。适于被密封地填充有流体的柔性塑料容器紧密地配合到泡沫元件的平面凹部中，以便在填充有合适的流体例如水时与其顶表面基本上共面。

7. 发明授权

US09274126B2 Risk factors and prediction of myocardial infarction 有权
标题翻译：危险因素和心肌梗死预测
公开(公告)号：US09274126B2
公开(公告)日：2016-03-01
申请号：US12946470
申请日：2010-11-15
申请人： Aram S. Adourian , Yu Guo , Xiaohong Li , Pieter Muntendam
发明人： Aram S. Adourian , Yu Guo , Xiaohong Li , Pieter Muntendam
IPC分类号： G01N33/68 , A61B5/00
CPC分类号： G01N33/6893 , G01N2800/324 , G01N2800/60
摘要： Biomarkers and methods are disclosed for diagnosing the risk of a myocardial infarction in an individual by measuring the levels of a set of biomarkers in a sample from an individual. A risk score is calculated for the individual by weighting the measured levels of the biomarkers. The risk score then is used to identify whether the individual is likely to experience a myocardial infarction. In addition, kits are disclosed that include a set of reagents for specifically measuring biomarker levels in a sample from an individual.
摘要翻译：公开了通过测量来自个体的样品中一组生物标志物的水平来诊断个体心肌梗塞风险的生物标志物和方法。通过对生物标志物的测量水平加权来计算个体的风险评分。然后，风险分数用于确定个体是否可能经历心肌梗死。此外，公开了包括用于特异性测量来自个体的样品中的生物标志物水平的一组试剂的试剂盒。

8. 发明申请

US20100143954A1 Galectin-3 Immunoassay 审中-公开
标题翻译： Galectin-3免疫测定
公开(公告)号：US20100143954A1
公开(公告)日：2010-06-10
申请号：US12608821
申请日：2009-10-29
申请人： Pieter Muntendam
发明人： Pieter Muntendam
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2333/4724 , G01N2800/325
摘要： The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
摘要翻译：本发明涉及用于特异性和定量检测样品中半乳凝素-3的方法和组合物。本发明的实施方案包括其中捕获结合部分和标记的结合部分特异性识别半乳凝素-3的N末端上的非重叠表位的检测测定。另外的实施方案涉及用于建立指示受试者的心力衰竭的存在和严重性的半乳凝素-3浓度的范围的方法以及基于半乳凝素-3浓度来预测受试者的临床结果的方法。

9. 发明申请

US20190314458A1 METHODS OF TREATING HORMONAL DISORDERS ASSOCIATED WITH ANDROGEN DEFICIENCY USING A REPEAT MICROFLARE DOSING REGIMEN 审中-公开
公开(公告)号：US20190314458A1
公开(公告)日：2019-10-17
申请号：US16379434
申请日：2019-04-09
申请人： Pieter Muntendam
发明人： Pieter Muntendam
IPC分类号： A61K38/22 , A61K31/4178
摘要： A method of treating a hormonal disorder associated with androgen deficiency is disclosed. The method includes administering a therapeutically effective dose of a composition having a GnRH agonist to a subject in need thereof. The therapeutically effective dose is sufficient to support a first flare of hormones. The method further includes allowing a time interval after the administration of the dose. The time interval is sufficient to support pituitary-gonadal axis recovery. The method further includes administering at least one subsequent dose of the composition to the subject after the time interval. The subsequent dose is sufficient to support a microflare of hormones that is less than, or equal to, a magnitude of the first microflare. Subsequent doses spaced by the time interval resulting in a repeat microflare sufficient to chronically elevate hormone levels and provide relief of signs or symptoms of androgen deficiency.

10. 发明授权

US08672857B2 Galectin-3 and cardiac resynchronization therapy 有权
标题翻译： Galectin-3和心脏再同步治疗
公开(公告)号：US08672857B2
公开(公告)日：2014-03-18
申请号：US12868612
申请日：2010-08-25
申请人： Pieter Muntendam
发明人： Pieter Muntendam
IPC分类号： A61B5/02
CPC分类号： G01N33/6893 , G01N2333/4724 , G01N2800/325 , G01N2800/52
摘要： The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.
摘要翻译：本发明涉及用于监测和预测心脏衰竭患者对心脏再同步治疗的生理反应的材料和方法。更具体地，本发明涉及内源蛋白半乳凝素-3及其在监测进行心脏再同步治疗的患者中疾病进展的用途，以及作为心脏再同步治疗反应的预测因子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式